Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Chinese medical devices are in health systems across U.S., and the government and hospitals are worried
How the FDA's approval for food additives works, and why experts say a loophole allows companies to bypass it
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Shares of Hims & Hers tumble 26% after FDA says semaglutide is no longer in shortage
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
UnitedHealth's rough stretch continues, with buyouts, a reported DOJ probe and a 23% drop in three months
